Articles with public access mandates - Vicky MakkerLearn more
Not available anywhere: 3
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome
DM Hyman, L Bakios, G Gualtiere, C Carr, RN Grisham, V Makker, ...
Gynecologic oncology 129 (1), 58-62, 2013
Mandates: US National Institutes of Health
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations
BJ Rimel, EK Crane, J Hou, J Nakayama, J MacDonald, K Lutz, V Makker, ...
Gynecologic Oncology 174, 148-156, 2023
Mandates: US National Institutes of Health
Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy
MH Chui, DN Brown, A Da Cruz Paula, EM da Silva, A Momeni‐Boroujeni, ...
The Journal of Pathology 262 (2), 129-136, 2024
Mandates: US National Institutes of Health, Susan G. Komen
Available somewhere: 89
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
V Makker, MH Taylor, C Aghajanian, A Oaknin, J Mier, AL Cohn, ...
Journal of clinical oncology 38 (26), 2981-2992, 2020
Mandates: US National Institutes of Health
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
V Makker, D Rasco, NJ Vogelzang, MS Brose, AL Cohn, J Mier, ...
The Lancet Oncology 20 (5), 711-718, 2019
Mandates: US National Institutes of Health
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ...
Annals of oncology 33 (9), 860-877, 2022
Mandates: US National Institutes of Health
Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors
MH Taylor, CH Lee, V Makker, D Rasco, CE Dutcus, J Wu, DE Stepan, ...
Journal of Clinical Oncology 38 (11), 1154-1163, 2020
Mandates: US National Institutes of Health
Endometrial cancer
V Makker, H MacKay, I Ray-Coquard, DA Levine, SN Westin, D Aoki, ...
Nature reviews Disease primers 7 (1), 88, 2021
Mandates: US National Institutes of Health
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial
F Meric-Bernstam, V Makker, A Oaknin, DY Oh, S Banerjee, ...
Journal of Clinical Oncology 42 (1), 47-58, 2024
Mandates: US National Institutes of Health
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ...
Cancer discovery 10 (5), 674-687, 2020
Mandates: US National Institutes of Health, Cancer Research UK, UK Engineering and …
Clinical utility of prospective molecular characterization in advanced endometrial cancer
TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ...
Clinical Cancer Research 24 (23), 5939-5947, 2018
Mandates: US National Institutes of Health
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI …
KL Jhaveri, XV Wang, V Makker, SW Luoh, EP Mitchell, JA Zwiebel, ...
Annals of Oncology 30 (11), 1821-1830, 2019
Mandates: US National Institutes of Health
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study
GF Fleming, VL Filiaci, B Marzullo, RJ Zaino, SA Davidson, M Pearl, ...
Gynecologic oncology 132 (3), 585-592, 2014
Mandates: US National Institutes of Health
Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping
MB Schiavone, O Zivanovic, Q Zhou, MM Leitao, DA Levine, RA Soslow, ...
Annals of surgical oncology 23, 196-202, 2016
Mandates: US National Institutes of Health
New therapies for advanced, recurrent, and metastatic endometrial cancers
V Makker, AK Green, RM Wenham, D Mutch, B Davidson, DS Miller
Gynecologic oncology research and practice 4, 1-12, 2017
Mandates: US National Institutes of Health
Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ...
Journal of Clinical Oncology 33 (34), 4099-4105, 2015
Mandates: US National Institutes of Health
Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study
O Zivanovic, DS Chi, Q Zhou, A Iasonos, JA Konner, V Makker, ...
Journal of Clinical Oncology 39 (23), 2594-2604, 2021
Mandates: US National Institutes of Health
Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion
CH Kim, F Khoury-Collado, EL Barber, RA Soslow, V Makker, ...
Gynecologic oncology 131 (3), 714-719, 2013
Mandates: US National Institutes of Health
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775
V Makker, N Colombo, AC Herráez, BJ Monk, H Mackay, AD Santin, ...
Journal of Clinical Oncology 41 (16), 2904-2910, 2023
Mandates: US National Institutes of Health
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I–IV uterine carcinosarcoma
V Makker, NR Abu-Rustum, KM Alektiar, CA Aghajanian, Q Zhou, ...
Gynecologic oncology 111 (2), 249-254, 2008
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program